ATE421590T1 - Zubereitungen und verfahren zur aktivierung bestimmter gene - Google Patents

Zubereitungen und verfahren zur aktivierung bestimmter gene

Info

Publication number
ATE421590T1
ATE421590T1 AT98935484T AT98935484T ATE421590T1 AT E421590 T1 ATE421590 T1 AT E421590T1 AT 98935484 T AT98935484 T AT 98935484T AT 98935484 T AT98935484 T AT 98935484T AT E421590 T1 ATE421590 T1 AT E421590T1
Authority
AT
Austria
Prior art keywords
methods
preparations
activation
certain genes
compositions
Prior art date
Application number
AT98935484T
Other languages
English (en)
Inventor
Charles Allen Black Jr
Original Assignee
Charles Allen Black Jr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charles Allen Black Jr filed Critical Charles Allen Black Jr
Application granted granted Critical
Publication of ATE421590T1 publication Critical patent/ATE421590T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT98935484T 1997-06-25 1998-06-24 Zubereitungen und verfahren zur aktivierung bestimmter gene ATE421590T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5077297P 1997-06-25 1997-06-25

Publications (1)

Publication Number Publication Date
ATE421590T1 true ATE421590T1 (de) 2009-02-15

Family

ID=21967329

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98935484T ATE421590T1 (de) 1997-06-25 1998-06-24 Zubereitungen und verfahren zur aktivierung bestimmter gene

Country Status (10)

Country Link
US (6) US6323003B1 (de)
EP (1) EP0993468B1 (de)
JP (1) JP2002507205A (de)
CN (1) CN1261373A (de)
AT (1) ATE421590T1 (de)
AU (1) AU738588B2 (de)
BR (1) BR9810460A (de)
CA (1) CA2293833A1 (de)
DE (1) DE69840502D1 (de)
WO (1) WO1998058944A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004046321A2 (en) 2002-11-15 2004-06-03 Trustees Of Boston University Cis/trans riboregulators
US7868011B2 (en) * 2003-04-09 2011-01-11 General Atomics Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2019194236A1 (ja) * 2018-04-06 2019-10-10 国立研究開発法人産業技術総合研究所 遺伝子発現を制御するための核酸

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ241310A (en) * 1991-01-17 1995-03-28 Gen Hospital Corp Trans-splicing ribozymes
JPH06505161A (ja) * 1991-01-25 1994-06-16 ユナイテッド・ステイツ・バイオケミカル・コーポレイション 核酸翻訳の調節
US6087484A (en) * 1992-02-04 2000-07-11 University Of Massachusetts Worcester Enhancement of ribozyme catalytic activity by A 2'-O-substituted facilitator oligonucleotide
GB9305759D0 (en) * 1993-03-19 1993-05-05 Medical Research Council And T Hiv therapy method and agents

Also Published As

Publication number Publication date
US20060134791A1 (en) 2006-06-22
US7919311B2 (en) 2011-04-05
EP0993468B1 (de) 2009-01-21
AU738588B2 (en) 2001-09-20
US6323003B1 (en) 2001-11-27
US7439059B2 (en) 2008-10-21
EP0993468A4 (de) 2006-02-01
WO1998058944A1 (en) 1998-12-30
US7052903B2 (en) 2006-05-30
US20020082236A1 (en) 2002-06-27
US20110171727A1 (en) 2011-07-14
US20090156794A1 (en) 2009-06-18
DE69840502D1 (de) 2009-03-12
JP2002507205A (ja) 2002-03-05
EP0993468A1 (de) 2000-04-19
CA2293833A1 (en) 1998-12-30
BR9810460A (pt) 2001-11-27
AU8472598A (en) 1999-01-04
CN1261373A (zh) 2000-07-26
US20070059836A1 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
KR960700752A (ko) 광범위한 종양억제 유전자와 유전자 생성물 그리고 종양억제 유전자 요법의 방법
FI973467A0 (fi) DNA-molekyylejä, valmistus ja käyttö geeniterapiassa
DE69128893T2 (de) Genetische veränderung von endothelzellen
ATE347360T1 (de) Verfahren zur induktion von krebszellentod und tumorregression
FI961621A (fi) Proteiini:farnesyylitranseraasin substituoidut tetra- ja pentapeptidi-inhibiittorit
WO1999016791A3 (en) Compounds and methods for regulating cell adhesion
DE69819124D1 (de) Lyophilisation von kultivierten, menschlichen zellen zur konservierung der rna und dna
ATE188257T1 (de) Benutzung von reagenzien abgeleitet vom menschlichen metastase unterdrückungs gen kai1 in diagnostischen und gen-terapeutischen verfahren
ES2187648T3 (es) Metodo para la administracion de farmacos para terapia genica.
IL128872A0 (en) TNF-beta-like protein for treating prostate cancer and related nucleic acid molecules pharmaceutical compositions and methods
WO2003008578A3 (en) Reagents and methods for identifying gene targets for treating cancer
ATE421590T1 (de) Zubereitungen und verfahren zur aktivierung bestimmter gene
ATE371031T1 (de) Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
BR9713744A (pt) Inibidores de cicloalquia da proteìna farnesil transferase
AU6113098A (en) Compositions for treatment of disorders involving programmed cell death
Martella CRISPR, epigenetics, and cancer
GEP20012440B (en) Biphenylsulfonamide Matrix Metalloproteinase Inhibitors
BR9810643A (pt) Genes e proteìnas de telomerase de vertebrado, eutilização dos mesmos
UA25582C2 (uk) Засіб для лікування гематоцитопенічних реакцій теплокровних організмів
ATE442591T1 (de) Krebsassoziierte nukleinsäure und proteine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties